Cemiplimab-Rwlc (NCT06449313)

Name: Cemiplimab-Rwlc trial for Non-small Cell Lung Cancer Stage III (NCT06449313)
Uploaded: 2026-10-31T07:17:18.156Z
Duration: 1 min 24 s
Description: Cemiplimab-Rwlc trial for Non-small Cell Lung Cancer Stage III (NCT06449313). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06449313.

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features: a one-minute explainerNCT064493131 min

Cemiplimab-Rwlc trial for Non-small Cell Lung Cancer Stage III (NCT06449313). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with selected high-risk stage three non-small-cell lung cancer considered suitable for surgery. No previous systemic treatment for this lung cancer is allowed. Non-squamous tumors require EGFR/ALK testing showing no alterations.

The idea: give four cycles of cemiplimab with chemotherapy before surgery, then cemiplimab for one year afterward. Cemiplimab blocks PD-1 to support immune attack. Postoperative radiation is optional if recommended. Researchers examine removed tissue for remaining cancer. Chemotherapy depends on tumor type.

This phase 2 study plans 21 patients. Georgetown's Joshua Reuss leads three recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.